Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7676738 | 0.95 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL7669928 | 0.93 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL7669711 | 0.91 | — | — | |
| SCHEMBL5393898 | 0.83 | HCAR2 (0.35) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL713102 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL265557 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL5411525 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL571438 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL22071002 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL3181237 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | claimed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | claimed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7176207-B2 | Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | US | disclosed |
| US-7026323-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | disclosed |
| US-6995156-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-02-07 | — | — | US | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-6861424-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HCRTR2, CNR2, CNR1 | SMN1; SMN2 370/4885MEN1 1758/4885KMT2A 123/4885 |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | SMN1; SMN2 4279/4885MEN1 2608/4885KMT2A 4517/4885 |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | SMN1; SMN2 370/4885MEN1 1758/4885KMT2A 123/4885 |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | SMN1; SMN2 4279/4885MEN1 2608/4885KMT2A 4517/4885 |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, HRH3, HCRTR1 | SMN1; SMN2 902/4885MEN1 949/4885KMT2A 92/4885 |
| US-20040142972-A1 | CNS target modulators | HCRTR2, CNR2, CNR1 | SMN1; SMN2 957/4885MEN1 2141/4885KMT2A 126/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | SMN1; SMN2 4038/4885MEN1 3054/4885KMT2A 4635/4885 |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, ADORA2B, TBXA2R | SMN1; SMN2 4340/4885MEN1 2462/4885KMT2A 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.